Innovent Showcases Preclinical Data of its First-in-Class IL-6 x TL1A Bispecific Antibody at ACR Convergence 2026

ملخص مفصل

PALO ALTO, Calif. and SUZHOU, China, Nov. 12, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops,…

PALO ALTO, Calif. and SUZHOU, China, Nov. 12, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular, and metabolic, ophthalmology and other major disease areas, presented for the first time the preclinical data of IAR177 as a poster in ACR Convergence 2026 held in Orlando, Florida. By simultaneously targeting two distinct pathways, IAR177 is designed to break the existing therapeutic ceiling of various rheumatic diseases. IAR177 is a thoughtfully designed molecule with the following features:

Dr. Huizhong Xiong, Vice President of Innovent Academy: "Rheumatic diseases are complex systemic illnesses that can cause extensive damage with limited efficacy. IAR177 is a rationally-designed and thoroughly optimized IL-6 x TL1A bispecific antibody. It can achieve higher efficacy and potentially disease modification and remission by profoundly suppressing two disease drivers through different stages and tissues of the disease. We hope it will provide patients with the next-generation of more effective treatment option, and become an integral part of our expanding rheumatology pipeline."

About IAR177 (IL-6/TL1A Bispecific Antibody) IAR177 is a bispecific antibody by Innovent Biologics that targets IL-6 and TL1A. Preclinical studies indicate that due to its unique epitope selection, IAR177 avoids the formation of immune complexes and effectively blocks various forms of target stimulants. Its superior disease-alleviating activity over single-target blockade is further validated in mouse disease models. Outstanding developability and pharmacokinetic profile in monkeys support a convenient clinical dosing regimen for this drug in the future.

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality…

Innovent has…

مطلع المقال، مقتطف من PR Newswire. لقراءة المقال كاملًا، افتحه على موقع الناشر.